Derek Archila
Stock Analyst at Wells Fargo
(3.69)
# 694
Out of 4,996 analysts
185
Total ratings
50%
Success rate
7.37%
Average return
Main Sectors:
Stocks Rated by Derek Archila
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CCCC C4 Therapeutics | Maintains: Overweight | $5 → $10 | $2.23 | +348.43% | 6 | Sep 23, 2025 | |
| ATYR aTyr Pharma | Downgrades: Equal-Weight | $25 → $1 | $0.84 | +18.98% | 3 | Sep 16, 2025 | |
| CLDX Celldex Therapeutics | Maintains: Overweight | $44 → $38 | $26.14 | +45.37% | 4 | Aug 20, 2025 | |
| SLNO Soleno Therapeutics | Initiates: Overweight | $123 | $64.96 | +89.35% | 1 | Aug 20, 2025 | |
| STRO Sutro Biopharma | Maintains: Equal-Weight | $4 → $3 | $0.89 | +238.37% | 1 | Aug 12, 2025 | |
| CABA Cabaletta Bio | Maintains: Equal-Weight | $3 → $2 | $2.36 | -15.25% | 11 | Aug 8, 2025 | |
| ASND Ascendis Pharma | Maintains: Overweight | $289 → $295 | $191.99 | +53.65% | 14 | Aug 8, 2025 | |
| ZNTL Zentalis Pharmaceuticals | Maintains: Equal-Weight | $6 → $5 | $1.55 | +222.58% | 5 | Aug 7, 2025 | |
| VRDN Viridian Therapeutics | Maintains: Equal-Weight | $27 → $26 | $20.18 | +28.84% | 2 | Aug 7, 2025 | |
| ARVN Arvinas | Maintains: Overweight | $19 → $16 | $8.27 | +93.47% | 7 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $67 → $89 | $82.70 | +7.62% | 9 | Aug 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $741 → $756 | $712.03 | +6.18% | 12 | Jul 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $17 | $4.05 | +319.75% | 1 | Jul 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $91 → $129 | $99.16 | +30.09% | 6 | Jul 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $57 → $53 | $56.25 | -5.78% | 8 | Jun 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $26 → $29 | $22.39 | +29.52% | 12 | Jun 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $11 → $18 | $17.45 | +3.15% | 4 | May 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $32 → $25 | $8.93 | +179.96% | 5 | Apr 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $11 → $10 | $7.49 | +33.51% | 5 | Mar 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $16 → $15 | $1.89 | +693.65% | 2 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $36 | $39.04 | -7.79% | 3 | Feb 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $40 → $51 | $23.58 | +116.28% | 3 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $12 → $14 | $16.60 | -15.66% | 5 | Dec 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $11 → $9 | $3.65 | +146.58% | 11 | Dec 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $47 → $45 | $16.23 | +177.26% | 9 | Dec 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $44 → $24 | $6.10 | +293.44% | 1 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $16 → $11 | $2.98 | +269.13% | 4 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $12 → $10 | $3.37 | +196.74% | 3 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $37 → $20 | $2.65 | +654.72% | 7 | May 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $6.05 | +197.52% | 1 | Aug 4, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $3.45 | - | 1 | Jul 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $298 → $193 | $33.78 | +471.34% | 1 | Jul 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $61 → $41 | $73.89 | -44.51% | 1 | Apr 15, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $480 → $160 | $16.00 | +900.00% | 3 | Mar 31, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $180 → $60 | $9.16 | +555.02% | 3 | Mar 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | $29 | $5.10 | +468.63% | 4 | Dec 11, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $34 → $50 | $1.21 | +4,032.23% | 2 | Jun 22, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $32 → $51 | $18.34 | +178.08% | 1 | Nov 15, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $88 | $21.45 | +310.26% | 1 | Sep 7, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | n/a | $25.24 | - | 1 | Sep 7, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $18.34 | - | 2 | Aug 3, 2017 |
C4 Therapeutics
Sep 23, 2025
Maintains: Overweight
Price Target: $5 → $10
Current: $2.23
Upside: +348.43%
aTyr Pharma
Sep 16, 2025
Downgrades: Equal-Weight
Price Target: $25 → $1
Current: $0.84
Upside: +18.98%
Celldex Therapeutics
Aug 20, 2025
Maintains: Overweight
Price Target: $44 → $38
Current: $26.14
Upside: +45.37%
Soleno Therapeutics
Aug 20, 2025
Initiates: Overweight
Price Target: $123
Current: $64.96
Upside: +89.35%
Sutro Biopharma
Aug 12, 2025
Maintains: Equal-Weight
Price Target: $4 → $3
Current: $0.89
Upside: +238.37%
Cabaletta Bio
Aug 8, 2025
Maintains: Equal-Weight
Price Target: $3 → $2
Current: $2.36
Upside: -15.25%
Ascendis Pharma
Aug 8, 2025
Maintains: Overweight
Price Target: $289 → $295
Current: $191.99
Upside: +53.65%
Zentalis Pharmaceuticals
Aug 7, 2025
Maintains: Equal-Weight
Price Target: $6 → $5
Current: $1.55
Upside: +222.58%
Viridian Therapeutics
Aug 7, 2025
Maintains: Equal-Weight
Price Target: $27 → $26
Current: $20.18
Upside: +28.84%
Arvinas
Aug 7, 2025
Maintains: Overweight
Price Target: $19 → $16
Current: $8.27
Upside: +93.47%
Aug 6, 2025
Upgrades: Overweight
Price Target: $67 → $89
Current: $82.70
Upside: +7.62%
Jul 31, 2025
Maintains: Overweight
Price Target: $741 → $756
Current: $712.03
Upside: +6.18%
Jul 25, 2025
Initiates: Overweight
Price Target: $17
Current: $4.05
Upside: +319.75%
Jul 10, 2025
Maintains: Overweight
Price Target: $91 → $129
Current: $99.16
Upside: +30.09%
Jun 26, 2025
Maintains: Overweight
Price Target: $57 → $53
Current: $56.25
Upside: -5.78%
Jun 2, 2025
Maintains: Equal-Weight
Price Target: $26 → $29
Current: $22.39
Upside: +29.52%
May 16, 2025
Maintains: Equal-Weight
Price Target: $11 → $18
Current: $17.45
Upside: +3.15%
Apr 9, 2025
Maintains: Overweight
Price Target: $32 → $25
Current: $8.93
Upside: +179.96%
Mar 21, 2025
Maintains: Equal-Weight
Price Target: $11 → $10
Current: $7.49
Upside: +33.51%
Mar 12, 2025
Maintains: Equal-Weight
Price Target: $16 → $15
Current: $1.89
Upside: +693.65%
Feb 24, 2025
Downgrades: Equal-Weight
Price Target: $36
Current: $39.04
Upside: -7.79%
Feb 13, 2025
Maintains: Overweight
Price Target: $40 → $51
Current: $23.58
Upside: +116.28%
Dec 19, 2024
Maintains: Equal-Weight
Price Target: $12 → $14
Current: $16.60
Upside: -15.66%
Dec 19, 2024
Maintains: Equal-Weight
Price Target: $11 → $9
Current: $3.65
Upside: +146.58%
Dec 19, 2024
Maintains: Overweight
Price Target: $47 → $45
Current: $16.23
Upside: +177.26%
Nov 15, 2024
Maintains: Overweight
Price Target: $44 → $24
Current: $6.10
Upside: +293.44%
Aug 12, 2024
Maintains: Overweight
Price Target: $16 → $11
Current: $2.98
Upside: +269.13%
May 15, 2024
Maintains: Overweight
Price Target: $12 → $10
Current: $3.37
Upside: +196.74%
May 5, 2021
Downgrades: Hold
Price Target: $37 → $20
Current: $2.65
Upside: +654.72%
Aug 4, 2020
Initiates: Buy
Price Target: $18
Current: $6.05
Upside: +197.52%
Jul 23, 2020
Upgrades: Buy
Price Target: n/a
Current: $3.45
Upside: -
Jul 10, 2020
Downgrades: Hold
Price Target: $298 → $193
Current: $33.78
Upside: +471.34%
Apr 15, 2020
Reiterates: Buy
Price Target: $61 → $41
Current: $73.89
Upside: -44.51%
Mar 31, 2020
Maintains: Hold
Price Target: $480 → $160
Current: $16.00
Upside: +900.00%
Mar 17, 2020
Downgrades: Hold
Price Target: $180 → $60
Current: $9.16
Upside: +555.02%
Dec 11, 2018
Downgrades: Perform
Price Target: $29
Current: $5.10
Upside: +468.63%
Jun 22, 2018
Maintains: Outperform
Price Target: $34 → $50
Current: $1.21
Upside: +4,032.23%
Nov 15, 2017
Maintains: Outperform
Price Target: $32 → $51
Current: $18.34
Upside: +178.08%
Sep 7, 2017
Initiates: Outperform
Price Target: $88
Current: $21.45
Upside: +310.26%
Sep 7, 2017
Initiates: Market Perform
Price Target: n/a
Current: $25.24
Upside: -
Aug 3, 2017
Downgrades: Perform
Price Target: n/a
Current: $18.34
Upside: -